Prostate Cancer: PSA, Gleason Score & Treatment Options

Prostate cancer begins when cells in the prostate, a walnut-sized gland that sits below the bladder and produces fluid for semen, grow and divide abnormally. It is one of the most frequently diagnosed cancers in men worldwide, and its behaviour is unusually variable: some tumours grow so slowly they may never cause symptoms or shorten life, while others are more aggressive and can spread beyond the prostate to lymph nodes, bones, or other organs.

Because of this wide range in behaviour, prostate cancer is not treated as a single disease. Instead, doctors classify each case into a risk category based on the PSA level, the extent of cancer felt on examination or seen on imaging, and how abnormal the cancer cells appear under the microscope. This risk-based approach helps avoid overtreating slow-growing tumours while ensuring that aggressive disease is treated promptly and thoroughly.

Most prostate cancers are adenocarcinomas, arising from the gland cells that produce prostatic fluid. The disease typically develops gradually over years, and many men are diagnosed after an elevated PSA blood test prompts further evaluation, often before any symptoms appear. Because of this, prostate cancer is frequently found at a localised, potentially curable stage in settings where PSA testing and follow-up biopsy pathways are well established.

Prostate cancer usually affects older men, with risk rising steadily after age 50, though it can occur earlier, particularly in men with a strong family history or certain inherited gene mutations. The disease is also more common and can be more aggressive in men of African descent, for reasons that are still being studied.

Understanding that a prostate cancer diagnosis does not automatically mean urgent, aggressive treatment is one of the most important messages in this field today. Many men live for decades with low-risk disease under careful monitoring, while others need immediate multi-modal treatment. Your care team will use the specific features of your cancer to place you into the risk group that best predicts your outlook and guides the treatment conversation.

If you have just been diagnosed, it can help to know that a large proportion of prostate cancers are detected at an early, localised stage with a generally favourable outlook. The specific combination of your PSA level, Gleason/ISUP grade, and imaging findings will determine whether your case is low, intermediate, or high risk, and this classification — not the word "cancer" alone — should guide the conversation about whether active surveillance, local treatment, or systemic therapy is most appropriate.

It is reasonable, and often recommended, to seek a second opinion before committing to a treatment path, especially for low- or intermediate-risk disease where several reasonable options may exist. Ask your urologist or oncologist to explain your risk group in plain terms and how it shaped the specific plan being recommended to you.

Early prostate cancer very often causes no symptoms at all, which is why PSA testing and, in some cases, digital rectal examination are used to detect it before problems arise. When symptoms do occur, they can include difficulty starting or stopping urination, a weak or interrupted urine stream, increased frequency of urination (especially at night), blood in the urine or semen, or discomfort in the pelvic area.

It is important to note that these urinary symptoms are also very common with non-cancerous conditions such as benign prostatic hyperplasia (enlarged prostate) or prostatitis (infection or inflammation of the prostate), which are far more frequent causes of these complaints than cancer. Nonetheless, new or worsening urinary symptoms should be evaluated by a clinician.

When prostate cancer has spread beyond the gland, additional symptoms can include bone pain (particularly in the back, hips, or pelvis, reflecting a tendency for prostate cancer to spread to bone), unexplained weight loss, fatigue, or swelling in the legs from lymph node involvement. These symptoms typically appear only with more advanced disease and should prompt prompt medical assessment.

Prostate cancer develops through the gradual accumulation of genetic changes in prostate gland cells that allow them to grow uncontrollably and evade the body's normal growth controls. Androgens, particularly testosterone and its more active form dihydrotestosterone, play a central role in stimulating the growth of both normal and cancerous prostate cells, which is why therapies that lower androgen levels or block their effect are a cornerstone of treatment.

A subset of prostate cancers, particularly those that are more aggressive or diagnosed at a younger age, are linked to inherited mutations in DNA-repair genes such as BRCA2, BRCA1, ATM, CHEK2, and genes associated with Lynch syndrome (such as MSH2 and MLH1). These mutations impair the cell's ability to repair DNA damage accurately, which can both increase cancer risk and, importantly, create a therapeutic vulnerability that can be exploited with certain targeted drugs.

Most prostate cancers, however, arise sporadically without a clearly identifiable inherited cause, reflecting a combination of age-related cellular changes, hormonal exposure over a lifetime, and factors that are not yet fully understood. Research continues into environmental and lifestyle contributors, though the evidence for most of these remains less definitive than for other cancer types.

The strongest risk factors for prostate cancer are non-modifiable: increasing age is the single most important factor, with most diagnoses occurring after age 50; family history of prostate cancer, particularly in a father or brother, roughly doubles risk; and men of African descent have a higher incidence and, on average, a higher risk of aggressive disease. Inherited mutations in BRCA2 and other DNA-repair genes substantially raise both the risk of developing prostate cancer and the likelihood that it will behave aggressively.

Modifiable and lifestyle-related factors appear to play a smaller but still relevant role. Obesity has been associated with a higher risk of aggressive prostate cancer and worse outcomes after diagnosis, while diets high in processed and red meat and low in vegetables have been studied as possible contributors, although the evidence is less conclusive than for other cancers. Regular physical activity may be associated with modestly lower risk and is generally recommended for overall health during and after cancer treatment.

Men with a strong family history of prostate, breast, ovarian, or pancreatic cancer, or with known inherited mutations in their family, are often encouraged to discuss earlier or more frequent PSA screening, as well as genetic counselling, with their physician.

Diagnosis usually begins with a PSA (prostate-specific antigen) blood test, sometimes combined with a digital rectal examination, prompted either by routine screening discussions or by urinary symptoms. An elevated or rising PSA does not confirm cancer — it can also be caused by an enlarged prostate, infection, or recent ejaculation — but it does prompt further evaluation, typically with a multiparametric MRI of the prostate.

MRI helps identify suspicious areas within the prostate and assign them a PI-RADS score reflecting the likelihood of clinically significant cancer, which helps target biopsies more precisely than in the past. If MRI or clinical findings raise concern, a prostate biopsy is performed, usually guided by ultrasound with MRI fusion, taking multiple tissue samples for pathology review.

The pathologist examines the biopsy tissue to confirm the presence of cancer and to assign a Gleason score and ISUP grade group, which describe how abnormal the cancer cells look and how likely the cancer is to grow and spread. If cancer is confirmed, further imaging such as bone scan, CT, or PSMA PET may be performed, particularly for higher-risk disease, to check whether the cancer has spread beyond the prostate.

Together, the PSA level, digital rectal exam findings, Gleason/ISUP grade, and imaging results are combined to assign a clinical stage and risk category (commonly very low, low, intermediate, high, or very high risk), which forms the basis for the treatment discussion.

Prostate cancer is staged using the TNM system, which describes the extent of the primary Tumour within and around the prostate, whether cancer has spread to regional lymph Nodes, and whether there is distant Metastasis to organs such as bone, liver, or lung. Stage I and II generally describe cancer confined to the prostate, Stage III often reflects local extension beyond the prostate capsule or seminal vesicles or a very high Gleason/ISUP grade, and Stage IV indicates spread to lymph nodes outside the pelvis or distant sites.

Alongside TNM stage, prostate cancer is commonly grouped into clinical risk categories — very low, low, favourable intermediate, unfavourable intermediate, high, and very high risk — based on PSA level, clinical stage, and Gleason/ISUP grade group together. This risk grouping is often more directly useful for treatment planning than TNM stage alone, because it captures how aggressive the cancer is likely to behave, not just how far it has physically spread.

For men with a rising PSA after initial local treatment (called biochemical recurrence), PSMA PET imaging is increasingly used to determine whether recurrent disease is confined to the prostate area or has spread elsewhere, which strongly influences whether further local treatment, systemic therapy, or a combination is recommended.

The Gleason score, assigned by a pathologist examining biopsy or surgical tissue under the microscope, grades the two most common patterns of cancer cell architecture on a scale of 3 to 5 and adds them together, producing scores typically ranging from 6 to 10. Because this scale is confusing to interpret at face value (a Gleason 6 sounds high but is actually the least aggressive category), pathology reports also include the ISUP grade group, a simplified 1-to-5 scale where Grade Group 1 corresponds to the least aggressive disease and Grade Group 5 to the most aggressive.

Genetic and genomic testing plays an increasingly important role, particularly for men with metastatic disease or a strong family history. Germline (inherited) testing for mutations in BRCA2, BRCA1, ATM, CHEK2, and Lynch syndrome genes is recommended for men with metastatic prostate cancer and is often offered to those with a significant family history, since results can identify eligibility for PARP inhibitor therapy and have implications for family members. Tumour tissue may also be tested for these same alterations (somatic testing) if germline testing is negative.

PSMA (prostate-specific membrane antigen) PET imaging is a specialised nuclear medicine scan that detects prostate cancer cells with high sensitivity, even in small amounts, using a radioactive tracer that binds to PSMA on the surface of cancer cells. It is used for initial staging of higher-risk disease, for detecting recurrence when PSA rises after treatment, and to help decide whether a patient with limited metastatic disease might benefit from PSMA-targeted radioligand therapy.

The vast majority of prostate cancers are adenocarcinomas arising from the glandular cells of the prostate, and essentially all discussion of Gleason/ISUP grading, PSA behaviour, and standard treatment pathways refers to this type. Adenocarcinomas themselves vary widely in aggressiveness, from indolent, very low-risk tumours to highly aggressive, rapidly progressive disease, which is why grading and risk stratification are so central to prostate cancer care.

A small proportion of prostate cancers show unusual or aggressive histological patterns, including ductal adenocarcinoma and intraductal carcinoma, which tend to behave more aggressively than typical adenocarcinoma and may prompt more intensive treatment even at earlier stages. Neuroendocrine (small cell) prostate cancer is a rare but aggressive subtype that behaves quite differently from typical adenocarcinoma, grows quickly, does not rely as heavily on androgen signalling, and is generally treated with chemotherapy-based approaches rather than hormone therapy alone.

An important biological distinction that emerges over the course of treatment, rather than at diagnosis, is castration-resistant prostate cancer — disease that continues to grow despite very low testosterone levels achieved through androgen deprivation therapy. This state requires a shift in treatment strategy toward additional hormonal agents, chemotherapy, PARP inhibitors, or PSMA-targeted radioligand therapy, depending on the individual case.

For very low- and low-risk localised prostate cancer, active surveillance is often the preferred approach: rather than treating immediately, the cancer is monitored closely with regular PSA tests, periodic MRI, and repeat biopsies, with treatment initiated only if the disease shows signs of progression. This strategy avoids or delays the side effects of surgery or radiotherapy in men whose cancer may never require treatment, while preserving the option to treat promptly if needed.

For localised disease that does require treatment, the main options are radical prostatectomy (surgical removal of the prostate, increasingly performed robotically) and radiotherapy, either external beam radiotherapy or brachytherapy (implanted radioactive seeds), sometimes combined with a short course of hormone therapy for intermediate- or high-risk disease. These approaches have broadly similar cure rates for localised disease, and the choice between them often depends on individual factors, side-effect profiles, and patient preference, making this an important area for shared decision-making with your care team.

Androgen deprivation therapy (ADT), which lowers testosterone through medications (commonly GnRH agonists or antagonists) or, less commonly, surgical removal of the testicles, is a cornerstone of treatment for higher-risk localised disease (usually combined with radiotherapy), biochemical recurrence, and metastatic disease. Because prostate cancer cells generally depend on androgen signalling to grow, lowering testosterone slows or shrinks the cancer in most patients, although side effects such as hot flushes, fatigue, loss of bone density, and sexual dysfunction are common and are actively managed by the care team.

For metastatic prostate cancer, ADT is often intensified from the start with the addition of a next-generation hormonal agent (such as an androgen receptor pathway inhibitor) or chemotherapy, an approach shown to improve survival compared with ADT alone. As disease progresses to castration-resistant prostate cancer, treatment options expand to include additional androgen receptor-targeted drugs, chemotherapy (commonly docetaxel or cabazitaxel), and, in men with qualifying DNA-repair gene mutations such as BRCA2, PARP inhibitors, which exploit the cancer cell's impaired ability to repair its own DNA.

PSMA-targeted radioligand therapy, which delivers targeted radiation directly to PSMA-expressing cancer cells throughout the body, has become an additional option for men with metastatic castration-resistant prostate cancer whose disease is confirmed to express PSMA on PET imaging and who have already received other standard treatments. Throughout all stages, supportive care addressing bone health, cardiovascular risk, sexual function, and psychological wellbeing is an important part of comprehensive prostate cancer management.

Prostate cancer survival statistics are generally favourable, particularly when the disease is confined to the prostate. According to population data such as the SEER database in the United States, the five-year relative survival rate for localised or regionally confined prostate cancer approaches nearly 100%, reflecting both the often slow-growing nature of the disease and the effectiveness of current local treatments and active surveillance strategies.

For prostate cancer that has spread to distant sites at diagnosis (metastatic disease), five-year relative survival is lower, commonly cited in the range of roughly 30-35%, though outcomes have been improving with the introduction of intensified upfront therapy combinations, PARP inhibitors for eligible patients, and PSMA-targeted radioligand therapy. Many men with metastatic prostate cancer live for several years with good quality of life under ongoing treatment, and the disease is often managed similarly to a chronic condition.

It is essential to understand that these figures are population averages drawn from large groups of patients and cannot predict any individual's outcome. Your specific PSA level, Gleason/ISUP grade, extent of disease, genetic test results, and response to treatment all influence your personal outlook, and your oncology team is best placed to discuss what the statistics mean in the context of your own case.